Navigation Links
Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
Date:2/11/2008

o was Under Secretary of Commerce for Economic Affairs. Prior to that, he was co-founder and Vice President of PPI. Dr. Shapiro also served as the principal economic advisor to Bill Clinton in his presidential campaign, senior economic advisor to Albert Gore, Jr. in 2000, Legislative Director for Senator Daniel P. Moynihan, and Associate Editor of U.S. News & World Report. He has been a Fellow of Harvard University, the Brookings Institution and the National Bureau of Economic Research. He holds a Ph.D. from Harvard, an A.B. from the University of Chicago and a M.Sc. from the London School of Economics and Political Science. He is the author of numerous articles for scholarly and popular journals, and his forthcoming book is Futurecast: How Superpowers, Globalization and Populations Will Change the Way You Live and Work, to be published by St. Martins Press in April 2008.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance i
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015 Kindred Biosciences, Inc. ... saving and improving the lives of pets, announced today that ... results on March 12, 2015 after the market close. The ... Time that day. Interested parties may access ... or (484) 756-4262 internationally, and using conference ID 98449349.  ...
(Date:3/3/2015)... 03, 2015 Cambridge Semantics, the leading ... technology, today announced that it has been named to ... in Knowledge Management.’ , To create the list ... analysts and system integrators who identify organizations dedicated to ... right information to the right people at the right ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and ... the addition of Jain PharmaBiotech,s new report ... to their offering. , Gene ... vectors, nonviral vectors and cell therapy with genetically ... of drug delivery and various routes of administration ...
(Date:3/3/2015)... , March 3, 2015 DNA Diagnostics Center ... in the world, celebrates its 20 th anniversary ... , DDC is a consumer services company that focuses ... employs over 200 associates and generates a significant portion ... over 120 countries. Peter Vitulli ...
Breaking Biology Technology:Cambridge Semantics Named to KMWorld’s 2015 ‘100 Companies That Matter in Knowledge Management’ 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3DNA Diagnostics Center, One of The World's Largest DNA Testing Labs, Celebrates Their 20th Anniversary 2DNA Diagnostics Center, One of The World's Largest DNA Testing Labs, Celebrates Their 20th Anniversary 3
... Conn., Feb. 14 Biodel Inc. (Nasdaq:,BIOD) today reported ... The net loss for the quarter was $11.0 million ... pivotal Phase III clinical trials of,VIAject(TM) positions us to ... the FDA by the end of 2008," stated Dr. ...
... Product that Meets Regulatory &, Health Issues ... ORLANDO, Fla., Feb. 14 Valensa International ... the extraction of,Haematococcus pluvialis for the manufacture of ... of recently growing demand for a,high-quality astaxanthin in ...
... 2007 Launch; Positioned for Expanded Growth in ... U.S. and International Markets, Fourth Quarter and 2007 Financial Highlights:, ... compared to net product sales of $21.8 million in Q3 2007., ... a GAAP net loss of $20.1 million, or $0.55 per share, ...
Cached Biology Technology:Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 2Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 3Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 4Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 5Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 6Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 7Valensa Expands Astaxanthin Extraction Capacity 2Alexion Reports Fourth Quarter and Full Year 2007 Results 2Alexion Reports Fourth Quarter and Full Year 2007 Results 3Alexion Reports Fourth Quarter and Full Year 2007 Results 4Alexion Reports Fourth Quarter and Full Year 2007 Results 5Alexion Reports Fourth Quarter and Full Year 2007 Results 6Alexion Reports Fourth Quarter and Full Year 2007 Results 7Alexion Reports Fourth Quarter and Full Year 2007 Results 8Alexion Reports Fourth Quarter and Full Year 2007 Results 9Alexion Reports Fourth Quarter and Full Year 2007 Results 10Alexion Reports Fourth Quarter and Full Year 2007 Results 11Alexion Reports Fourth Quarter and Full Year 2007 Results 12Alexion Reports Fourth Quarter and Full Year 2007 Results 13
(Date:2/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT METHOD ... a new groundbreaking payment method. Payment accounts may be ... only be accessed if both the speech (the word ...
(Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:2/12/2015)... Feb. 12, 2015   MedNet Solutions , ... clinical study management systems, has recently bolstered its ... distinguishing iMedNet as the ... (CROs) and healthcare consultants.  Building on the Program,s ... referrals and numerous co-marketing opportunities), MedNet,s new and ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... threatened by exotic species of the moon jellyfish being ... Using genetic data and computer simulations of ocean currents ... South Wales and the University of California, Davis, have ... naturally, according to a report in today's Proceedings of ...
... has discovered how a gene that suppresses the development of ... way to treatments based on the function of the gene. ... Hormel Institute in Austin, Minn., have applied for a patent ... July 10 in the journal Nature Structural & Molecular Biology. ...
... suggested that ancient Neanderthals might have had an accelerated childhood ... based on a new assessment by researchers from Ohio State ... found that the rate of tooth growth present in the ... different populations of modern humans. , And since the ...
Cached Biology News:Ships bring alien jellyfish invaders to our shores 2Neanderthal teeth grew no faster than comparable modern humans' 2Neanderthal teeth grew no faster than comparable modern humans' 3
This kit is designed to select cells labeled with fluorescein isothiocyanate- (FITC-) conjugated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
... described by end-users to be "a delight ... of light microscopy and electronic imaging. With ... does not require much space and can ... environment. The DM-BA300 combines Motic's own revolutionary ...
lid holder -see Blotters (Semi-Dry) for more info...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD69 TAC is designed to deplete human CD69 from samples to isolate resting CD4+ or CD8+ T cells....
Biology Products: